Challenge:
A clinical stage biotech company developing novel oncology treatments was planning a private funding round to progress the clinical development of its lead product. The biotech requested Alacrita’s assistance in conducting a valuation of the business to assist in fund-raising.
Solution:
Alacrita developed a risk-adjusted net present value (rNPV) for the company’s most advanced asset, overlaid with a Monte Carlo simulation to provide a value range for the asset. We also developed an estimated valuation for the technology platform as a whole. We produced projections for addressable market, peak penetration, pricing and the associated product revenues in the major markets. We similarly developed projections for costs, timelines and probabilities of success at each go/no-go point. The remainder of the available opportunity was estimated as a multiple of the major market opportunity.